<DOC>
	<DOC>NCT00819780</DOC>
	<brief_summary>The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.</brief_summary>
	<brief_title>PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologicallyconfirmed adenocarcinoma of the colon or rectum in patients with unresectable metastatic (M1) disease Patients with at least 1 unidimensionally measurable lesion of at least 10 mm per modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines Wildtype KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 Men or women 18 years of age or older Adequate hematologic, renal, hepatic, metabolic, and coagulation function History of prior or concurrent central nervous system (CNS) metastases Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma Clinically significant cardiac disease Clinically significant peripheral sensory neuropathy Active inflammatory bowel disease Recent gastroduodenal ulcer to be active or uncontrolled History of interstitial lung disease Recent pulmonary embolism, deep vein thrombosis, or other significant venous event Preexisting bleeding diathesis and/or coagulopathy with exception of wellcontrolled anticoagulation therapy Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>modified FOLFOX 6</keyword>
	<keyword>mFOLFOX 6</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>First-Line</keyword>
	<keyword>metastatic</keyword>
</DOC>